OpenAI has recently published a detailed architecture description of the Codex App Server, a bidirectional protocol that decouples the Codex coding agent's core logic from its various client surfaces.

THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, ...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and ...

Lexicon Inc., a Little Rock-based construction management and steel fabrication company, said Thursday it has become a private, employee-owned company. Lexicon said the decision comes after a ...

Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...

There is a lot of enterprise data trapped in PDF documents. To be sure, gen AI tools have been able to ingest and analyze PDFs, but accuracy, time and cost have been less than ideal. New technology ...

Acquisition strengthens QIAGEN’s presence in the rapidly growing single-cell market, accelerating growth across its industry-leading Sample technologies portfolio Parse provides Evercode, a highly ...

Sept 22 (Reuters) - Lexicon Pharmaceuticals (LXRX.O), opens new tab said on Monday the U.S. Food and Drug Administration requires more time to review the company's previously submitted additional data ...

(Reuters) -Lexicon Pharmaceuticals said on Monday the U.S. Food and Drug Administration requires more time to review the company's previously submitted additional data on its experimental drug, ...

State officials Hugh McDonald and Mike Rogers join Lexicon in honoring 40 employees as they graduate from the company’s unique workforce development initiative LITTLE ROCK – Lexicon, Inc., recognized ...

A Houston-area company has just inked a massive, $1 billion deal to become the next big weight-loss medication maker. The timeline for the company to begin receiving payments is dependent on the ...